xCures has closed a $46 million Series B financing led by Innovius Capital, with iGrow, GKCC, Spring Mountain Capital, and existing investors joining the round. The healthcare-data company said the capital will accelerate development of its Clinical Clarity Engine, the AI system it uses to turn fragmented medical records into structured data that providers, diagnostics labs, and value-based care organizations can act on.
Patient information today is scattered across thousands of labs, hospitals, imaging centers, and electronic medical records — most of it arriving as unstructured documents that are difficult to feed into clinical workflows. xCures says its Clinical Clarity Engine pulls signal from that exhaust through three integrated capabilities: decision-ready checklists, automated patient histories built on those checklists, and evidence-grade data outputs. To date, the platform has processed more than 300 million medical records sourced from over 550,000 healthcare locations nationwide, supporting clinical decisions for millions of U.S. patients.
"Healthcare has spent decades generating enormous amounts of patient data without a reliable way to make that information usable. We're changing that," said Mika Newton, CEO of xCures. "This financing allows us to accelerate product development, expand our team, and help more organizations turn fragmented records into information they can actually act on."
The round is a bet on a thesis institutional investors have been chasing for years: that the value of AI in healthcare is gated on the quality and completeness of the underlying clinical data, not the sophistication of the models reading it. Stu Posluns, partner at Innovius, framed the company's position bluntly.
"The promise of AI in healthcare depends on having accurate, complete, and trustworthy clinical data," Posluns said. "xCures has built by far the most compelling platform we've seen for turning fragmented medical records into actionable clinical intelligence. We're proud to support Mika and the team as they expand that impact across healthcare."
The funding will be channeled into faster product development, headcount growth, and broader deployment across providers, diagnostics labs, and consumer health platforms. The Engine delivers its outputs through both a web interface and a developer-facing API, with every answer tied back to its source document — a provenance design xCures argues is essential for adoption in regulated clinical settings where unverifiable AI outputs are non-starters.
xCures' bet sits at the intersection of two trends institutional capital has been steadily backing: value-based care models that pay for outcomes rather than procedures, and a wave of healthcare-AI investment dependent on cleaner upstream data infrastructure. The company's earlier work focused on advanced cancer patient data; it has since expanded across conditions and record types as more provider organizations push for structured longitudinal patient histories that survive transitions between health systems.
The Series B caps a stretch in which healthcare-data infrastructure has become one of the more durable financing themes inside enterprise tech, even as broader AI valuations have whipsawed across the rest of the market.